Olivier S. Descamps
Olivier S. Descamps has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
A. De Meester
Department of Internal Medicine
1 shared publicationF. Chenot
Department of Internal Medicine, Centre Hospitalier Jolimont-Lobbes, Haine Saint-Paul, Belgium
1 shared publicationFrancis R. Heller
**Department of Obstetrics and Gynecology, Centre Hospitalier Jolimont-Lobbes, Haine Saint-Paul, Belgium
1 shared publicationM. Blaimont
Department of Internal Medicine
1 shared publicationMonique Bruniaux
**Department of Obstetrics and Gynecology, Centre Hospitalier Jolimont-Lobbes, Haine Saint-Paul, Belgium
1 shared publicationO. Marcovitch
Department of Internal Medicine
1 shared publication
Latest Publications
- 24 April 2007
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 37 (5) , 357-363
Co‐administration of ezetimibe and simvastatin in acute myocardial infarction
Background Recent trials in acute myocardial infarction indicate that intensive and early statin therapy that lowers low‐density lipoprotein cholesterol (LDL‐C) to ≤ 70 mg dL−1 is beneficial. The combination of statins with ezetimibe, a newly developed cholesterol‐absorption inhibitor, can lead to a further reduction in LDL‐C of up to 26%. In this study, we examined the rapidity and intensity of the lipid‐lowering effect of ezetimibe co‐administered with simvastatin immediately after myocardial infarction.Materials and methods Sixty patients admitted for acute myocardial infarction were randomized to receive either simvastatin 40 mg (SIMVA), a combination of simvastatin 40 mg and ezetimibe 10 mg (EZE/SIMVA), or no lipid‐lowering drugs (NLLD) and had their lipid levels assessed 2, 4 and 7 days later.Results At baseline, cardiovascular risk factors were similar in all three groups [mean (SD) LDL‐C of 141 (36) mg dL−1]. At days 2 , 4 and 7 there was no significant change in mean LDL‐C levels in the NLLD group (−10%, −6%, and −9%, all P > 0·09), while there were significant reductions with SIMVA (−15%, −27%, and −25%, respectively, all P < 0·001 vs. day 0) and even greater reductions with co‐administration of EZE/SIMVA (−27%, −41%, and −51%, respectively, all P < 0·001 vs. day 0). The percentages of patients achieving LDL‐C below 70 mg dL−1 at days 4 and 7 were substantially greater with EZE/SIMVA (45% and 55%, respectively) than with SIMVA (5% and 10%, respectively), while no NLLD patient reached this goal. Triglyceride levels showed a progressive increase in the NLLD group (+45% at day 7, P < 0·05 vs. day 0), no change in the SIMVA group, but a decrease in the EZE/SIMVA group (−17% at day 7, P < 0·05 vs. day 0). No significant difference in HDL‐C levels, tolerability, or clinical events was observed between the three groups.Conclusions The co‐administration of ezetimibe 10 mg with simvastatin 40 mg, by inhibiting cholesterol absorption and production, allowed more patients with acute myocardial infarction to reach LDL‐C ≤ 70 mg dL−1 as early as the fourth day of treatment. The effects of such rapid and intense reduction in LDL‐C on cardiovascular morbidity and mortality need to be evaluated in future clinical endpoint studies.
- 24 April 2007
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 37 (5) , 357-363
Co‐administration of ezetimibe and simvastatin in acute myocardial infarction
Background Recent trials in acute myocardial infarction indicate that intensive and early statin therapy that lowers low‐density lipoprotein cholesterol (LDL‐C) to ≤ 70 mg dL−1 is beneficial. The combination of statins with ezetimibe, a newly developed cholesterol‐absorption inhibitor, can lead to a further reduction in LDL‐C of up to 26%. In this study, we examined the rapidity and intensity of the lipid‐lowering effect of ezetimibe co‐administered with simvastatin immediately after myocardial infarction.Materials and methods Sixty patients admitted for acute myocardial infarction were randomized to receive either simvastatin 40 mg (SIMVA), a combination of simvastatin 40 mg and ezetimibe 10 mg (EZE/SIMVA), or no lipid‐lowering drugs (NLLD) and had their lipid levels assessed 2, 4 and 7 days later.Results At baseline, cardiovascular risk factors were similar in all three groups [mean (SD) LDL‐C of 141 (36) mg dL−1]. At days 2 , 4 and 7 there was no significant change in mean LDL‐C levels in the NLLD group (−10%, −6%, and −9%, all P > 0·09), while there were significant reductions with SIMVA (−15%, −27%, and −25%, respectively, all P < 0·001 vs. day 0) and even greater reductions with co‐administration of EZE/SIMVA (−27%, −41%, and −51%, respectively, all P < 0·001 vs. day 0). The percentages of patients achieving LDL‐C below 70 mg dL−1 at days 4 and 7 were substantially greater with EZE/SIMVA (45% and 55%, respectively) than with SIMVA (5% and 10%, respectively), while no NLLD patient reached this goal. Triglyceride levels showed a progressive increase in the NLLD group (+45% at day 7, P < 0·05 vs. day 0), no change in the SIMVA group, but a decrease in the EZE/SIMVA group (−17% at day 7, P < 0·05 vs. day 0). No significant difference in HDL‐C levels, tolerability, or clinical events was observed between the three groups.Conclusions The co‐administration of ezetimibe 10 mg with simvastatin 40 mg, by inhibiting cholesterol absorption and production, allowed more patients with acute myocardial infarction to reach LDL‐C ≤ 70 mg dL−1 as early as the fourth day of treatment. The effects of such rapid and intense reduction in LDL‐C on cardiovascular morbidity and mortality need to be evaluated in future clinical endpoint studies.
- Open Access
- 1 November 2005
- Published by Elsevier in Journal of Lipid Research
- Vol. 46 (11) , 2405-2414
Lipoprotein metabolism of pregnant women is associated with both their genetic polymorphisms and those of their newborn children
- 1 November 2005
- Published by Elsevier in Journal of Lipid Research
- Vol. 46 (11) , 2405-2414
Open AccessLipoprotein metabolism of pregnant women is associated with both their genetic polymorphisms and those of their newborn children